Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hypertrophic cardiomyopathy in which the cause of the disease is a mutation in the MYH6 gene.
Features include always present findings: Thickened heart muscle (hypertrophic cardiomyopathy), Thickened left heart wall (left ventricular hypertrophy), Congestive heart failure, and Complete right bundle branch block and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 7 | Thickened heart muscle (hypertrophic cardiomyopathy), Thickened left heart wall (left ventricular hypertrophy), Congestive heart failure |
MYH6 encodes myosin heavy chain 6 (1,939 aa). Muscle contraction Highest expression in Heart Atrial Appendage (4,609 TPM) and Heart Left Ventricle (334.6 TPM).
Hypertrophic cardiomyopathy 14 is associated with mutations in the MYH6 gene on chromosome 14.
MYH6 is classified as a druggable target (Druggable Genome category) with score 2.5.
Genetic testing for MYH6 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypertrophic cardiomyopathy 14 has been reported in the published literature.
Phenotype severity distribution: 7 always present features.
No clinical trials have been registered for hypertrophic cardiomyopathy 14.
272 publications have been identified in PubMed for hypertrophic cardiomyopathy 14. Kisho has analyzed 142 by research type. Research spans Epidemiology / Natural History (25%), Review / Meta-Analysis (25%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 36 | 25% |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 8:33 PM UTC
Online Mendelian Inheritance in Man
Research summaries |
35 |
25% |
Clinical study results | 24 | 17% |
Laboratory research | 18 | 13% |
Testing and diagnosis research | 15 | 11% |
New treatment approaches | 6 | 4% |
Other research | 5 | 4% |
Patient case studies | 3 | 2% |
Aimo A (2026). [PMID: 41591616](https://pubmed.ncbi.nlm.nih.gov/41591616/). *Int J Cardiovasc Imaging*. [Epidemiology / Natural History]
Rossano JW (2026). [PMID: 41910394](https://pubmed.ncbi.nlm.nih.gov/41910394/). *N Engl J Med*. [Basic Science / Preclinical]
Masri A (2026). [PMID: 40285763](https://pubmed.ncbi.nlm.nih.gov/40285763/). *JACC Heart Fail*. [Clinical Trial Publication]
Abramowitz SA (2026). [PMID: 41433035](https://pubmed.ncbi.nlm.nih.gov/41433035/). *JAMA Cardiol*. [Epidemiology / Natural History]
Ma X (2026). [PMID: 41074892](https://pubmed.ncbi.nlm.nih.gov/41074892/). *JACC Cardiovasc Imaging*. [Epidemiology / Natural History]
Hao L (2026). [PMID: 41695390](https://pubmed.ncbi.nlm.nih.gov/41695390/). *Front Cell Dev Biol*. [Review / Meta-Analysis]
Jain SS (2026). [PMID: 41213043](https://pubmed.ncbi.nlm.nih.gov/41213043/). *JAMA Cardiol*. [Clinical Trial Publication]
Song Y (2026). [PMID: 41218064](https://pubmed.ncbi.nlm.nih.gov/41218064/). *Eur Heart J Cardiovasc Imaging*. [Diagnostic / Biomarker]
Sardu C (2026). [PMID: 41751224](https://pubmed.ncbi.nlm.nih.gov/41751224/). *Biomedicines*. [Other]
Alasmar R (2026). [PMID: 41838376](https://pubmed.ncbi.nlm.nih.gov/41838376/). *Am J Cardiovasc Drugs*. [Epidemiology / Natural History]